survival benefit of cytoreductive nephrectomy in contemporary metastatic renal cell carcinoma, CARMENA trial, renal cancer, renal cell carcinoma patients, cytoreductive nephrectomy.
Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive…
prostate cancer, external beam radiotherapy (EBRT), prostate brachytherapy boost, High Dose Rate prostate brachytherapy boost, Low Dose Rate prostate brachytherapy boost, Quality of Life after…
David Crawford discusses advancements in advanced urothelial cancer treatment with Daniel Petrylak. Dr. Petrylak highlights the success of enfortumab vedotin (EV), an antibody-drug conjugate targeting…
Zach Klaassen and Kelvin Moses discuss the continuum of care for metastatic hormone-sensitive prostate cancer, focusing on triplet therapy. Dr. Moses highlights the ideal patient…
Zach Klaassen facilitates a conversation on the continuum of care in metastatic hormone-sensitive prostate cancer (mHSPC) with Jason Hafron and Elisabeth Heath. The discussion underscores…
Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity’s focus on copper isotopes, particularly Copper-67 (Cu-67 or…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate…
Pat Hensley hosts a discussion on the role of pelvic lymphadenectomy during radical cystectomy for muscle invasive bladder cancer. Joining him are Dr. Seth Lerner…
Radioligand Therapy, metastatic castrate-resistant prostate cancer (mCRPC), androgen receptor pathway inhibitors (ARPIs), Radium-223 (Xofigo®) for mCRPC, Lutetium 177 vipivotide tetraxetan (PLUVICTO®).
